Navigation Links
DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
Date:8/28/2007

SOMERSET, N.J., Aug. 28 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. ("DOV" or the "Company") (OTC Bulletin Board and Pink Sheets: DOVP) announced today that its common stock is now being quoted on the OTC Bulletin Board. The Company understands that its common stock is also still being quoted on the Pink Sheets.

"We are pleased that shares of our common stock are now being quoted both on the OTC Bulletin Board and the Pink Sheets," said Barbara Duncan, Chief Executive Officer of DOV. "We believe this dual quotation on the OTC Bulletin Board and the Pink Sheets provides the Company with greater visibility in the investment community and offers our shareholders, both current and future, greater liquidity."

About DOV

DOV is a biopharmaceutical company focused on the discovery, acquisition and development of novel drug candidates for central nervous system disorders. The Company's product candidates address some of the largest pharmaceutical markets in the world including depression, pain and insomnia.

Cautionary Note

Statements in this press release that are not historical facts constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. You can also identify forward-looking statements by the following words: may, will, should, expect, intend, plan, anticipate, believe, estimate, predict, potential, continue or the negative of these terms or other comparable terminology. We caution you that forward-looking statements are inherently uncertain and are simply point-in-time estimates based on a combination of facts and factors currently known by us about which we cannot be certain or even relatively confident. Actual results or events will surely differ and may differ materially from our forward-looking statements as a result of many factors, some of which we may not be able to predict or may not be within our control. Such factors may also materially adversely affect our ability to achieve our objectives and to successfully develop and commercialize our product candidates, including our ability to:

-- raise substantial additional capital in order to fund operations;

-- obtain and maintain all necessary patents, licenses and other

intellectual property rights;

-- demonstrate the safety and efficacy of product candidates at each

stage of development;

-- meet our development schedule for our product candidates, including

with respect to clinical trial initiation, enrollment and completion;

-- meet applicable regulatory standards and receive required regulatory

approvals on our anticipated time schedule or at all;

-- meet or require our partners to meet obligations and achieve

milestones under our license and other agreements;

-- maintain collaborations as required with pharmaceutical partners;

-- seek and evaluate strategic alternatives, including with respect to

collaborations and partnerships for certain of our development

programs and compounds; and

-- produce drug candidates in commercial quantities at reasonable costs

and compete successfully against other products and companies.

You should also refer to the risks discussed in our filings with the Securities and Exchange Commission including those contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006 that was filed on March 30, 2007 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 that was filed on August 8, 2007. We qualify all our forward- looking statements by these cautionary statements. Readers should not place undue reliance on our forward-looking statements. We do not undertake any obligation and do not intend to update any forward-looking statement.


'/>"/>
SOURCE DOV Pharmaceutical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DeForest biodiesel plant begins production
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. Prodesse begins clinical trials for flu virus detection
4. Closing the income gap begins with education
5. Corporate control begins with a strong board
6. Emerging game developer begins work on prototypes
7. GE begins human trials for cancer detection agent
8. Now the real work begins
9. Esker begins automated faxing and mailing service
10. Its not exactly OPEC, but Midwest states are trading ideas on biofuels
11. Avoid Trading Tech Relationships Like Pokmon Cards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... NC (PRWEB) , ... November 30, 2016 , ... ... engaged in the development of a new orally administered treatment for Alzheimer’s disease ... neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild to ...
(Date:11/30/2016)... ... November 30, 2016 , ... With growth rates averaging more ... five years and look forward to continuing their expansion in their new office space. ... which has been traditionally favoured by the creative industries, so Random42 Scientific Communication will ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and groundbreaking venture founded by Arianna Huffington, as part of the Thrive Global ... Gut Explorer Kit, enabling purchasers to explore the microorganisms in their gut, collectively ...
(Date:11/30/2016)... The global  HIV-1 therapeutics market  is expected to reach a value of USD ... new report by Grand View Research, Inc., HIV continues to be one of ... Reading ... Grand View Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) ...
Breaking Biology Technology:
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/22/2016)... India , November 22, 2016 According to ... (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and ... 2022", published by MarketsandMarkets, the market is expected to grow from USD ... a CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
Breaking Biology News(10 mins):